Sepragen signs CB FINPRA as a distributor for its products in RUSSIA

March, 2010, Hayward, CA...Sepragen signed a distribution agreement for its products with CB FINPRA for the Russian and Kazakhstan market. CB FINPRA has been a distributor for various biotech products and instrumentation that they supply to research institutes and biotechnology companies in Russia, Kazakhstan and other countries. “We are excited about working with Sepragen to bring new technologies for upstream and downstream processing to biotechnology and pharmaceutical companies and institutes. Sepragen’s products such as Superflo Radial Flow Chromatography Columns and Quantasep automated purification systems are already being used successfully by several customers in Russia. We are proud to offer these advanced products to our customers in the Russian market to both new and established Sepragen customers”, said a spokesperson for CB FINPRA. “We can also provide service and support for these products” said a FINPRA representative. Vinit Saxena, Sepragen’s CEO said that he looked forward to working with CB FINPRA in providing innovative products to the Russsian and Kazakhstan market.

Sepragen currently provides innovative bio-processing products that enable biotech companies to develop and produce biopharmaceuticals quickly and cost-effectively. Sepragen products are used world-wide by leading biotech companies to manufacture over twenty FDA approved drugs.

Return to News and Events main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.